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(a) Piroxicam 
Non-steroidal anti-inflammatory drug 
Molecular weight: 331.35 
Water solubility: 23 ȝg/mL at 22 °C 
Melting point: 201 °C 
(b) Pranoprofen 
Non-steroidal anti-inflammatory drug 
Molecular weight: 255.27 
Water solubility: 47 ȝg/mL at 25 °C 
Melting point: 186 - 190 °C 
Fig. 1  Chemical structures and physicochemical properties of (a) pirox-
icam and (b) pranoprofen 
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Sodium Dodecyl Sulfate (SDS) 
Anionic surfactant 
Molecular weight: 288.38 
Critical micelle concentration at 20 °C: 8.2 mM (2.4 mg/mL) 
Melting point: 204 - 207 °C 
Fig. 2  Chemical structures and physicochemical properties of the 
pharmaceutical excipient (surfactant) used in this study. 
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(R' = -C18H37)
Hydroxyethylcellulose (HEC)
Molecular weight: 500,000 
Glass transition (Tg): 106 °C 
Hydroxypropylcellulose (HPC)
Molecular weight: 15,000 - 30,000 
Glass transition (Tg): 60 - 75 °C 
Hydrophobically modified 
Hydroxypropylmethylcellulose 
(HM-HPMC) 
Molecular weight: 400,000 
Glass transition (Tg): 135 °C 
Fig. 3-1  Chemical structures and physicochemical properties of the 
pharmaceutical excipients (polymer) used in this study. 
O
O
OR
OOH
OR
OR
H
RO
RO
RO
R
OR * O H
n
x
R = H or
O
O
OR
OOH
OR
OR
H
RO
RO
RO
R
OR
* O H
CH3
n
x
R = H or
̆ 8 ̆
Hydroxypropylmethylcellulose 
(HPMC)
Molecular weight: 16,000
Glass transition (Tg): 155 °C

Propylene glycol alginate (PGA)
Molecular weight: 10,000 
Glass transition (Tg): 250 °C 
Polyvinyl alcohol (PVA)
Molecular weight: 24,000 
Glass transition (Tg): 62 °C
Fig. 3-2  Chemical structures and physicochemical properties of the 
pharmaceutical excipients (polymer) used in this study. 
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(2) ⹜ᢱ⺞⵾ᣇᴺ
Physical mixture (PM)
ࡇࡠࠠࠪࠞࡓ޽ࠆ޿ߪࡊ࡜ࡁࡊࡠࡈࠚࡦ (0.5 g)ޔ᳓ṁᕈ㜞ಽሶ (1.5 g)෸߮
SDS (0.5 g)ࠍ⾰㊂Ყ 1:3:1ߢࠟ࡜ࠬ⵾ࡃࠗࠕ࡞ߦ⒊㊂ߒߚᓟޔࡏ࡞࠹࠶ࠢࠬࡒ
ࠠࠨ࡯ࠍ૶↪ߒߡ 5ಽ㑆‛ℂ⊛ߦᷙวߒޔPMࠍ⺞⵾ߒߚ (Scheme 1)ޕ
Ground mixture (GM)
᳓ṁᕈ㜞ಽሶߣߒߡ HPMCޔHM-HPMCޔPGA෸߮ HECࠍ૶↪ߒߚ႐วߩ
PMߪޔᝄേဳࡠ࠶࠼ࡒ࡞ (TI-200ޔᐔᎿ⵾૞ᚲ␠⵾)ࠍ↪޿ߡቶ᷷᧦ઙਅߢ
60ಽ㑆☳⎈ߒޔGMࠍ⺞⵾ߒߚޕHPC෸߮ PVAࠍ૶↪ߒߚ႐วߩ PMߪޔᝄ
േဳࡠ࠶࠼ࡒ࡞ (TI-500ޔᐔᎿ⵾૞ᚲ␠⵾)ࠍ↪޿ߡ í180 °C᧦ઙਅߢ 60ಽ㑆
☳⎈ߒޔGMࠍ⺞⵾ߒߚ (Scheme 1)ޕ
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Scheme 1  Manufacturing process of physical mixtures and ground 
mixtures.
Ground mixture
Physical mixture
Piroxicam
or
Pranoprofen
Water-soluble polymers SDS
1:3:1 (weight ratio) 
Room temperature 
or
í180 °C 
Vibrational rod mill 
for 60, 90, 120, 180 
or 240 min 
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(3) ᷹ቯᣇᴺ
☸ᐲಽᏓ᷹ቯ
GM☳૕ࠍ⫳⇐᳓ߦಽᢔߐߖޔ2ಽ㑆ߩ⿥㖸ᵄಣℂߦࠃࠅࠦࡠࠗ࠼⁁ Ộᶧ
ߩ⹜ᢱࠍ⺞⵾ߒޔ☸ᐲಽᏓ᷹ቯࠍⴕߞߚޕ
㧨ⵝ⟎㧪
Microtrac UPA® (UPT-UT151)ޔᣣᯏⵝ␠⵾
᷹ቯ▸࿐ : 0.003 㨪 6 μm 
ේℂ : േ⊛శᢔੂᴺ
㧨᷹ቯ᧦ઙ㧪
᷹ቯᤨ㑆 : 180⑽
᷹ቯ᷷ᐲ : 25 °C 
☳ᧃ X✢࿁᛬(PXRD)᷹ቯ
☳ᧃ⹜ᢱࠍࠟ࡜ࠬࡊ࡟࡯࠻ߦలႯߒޔ⴫㕙ࠍဋ৻ߦߒߡᄢ᳇࿶ਅޔቶ᷷ߢ
᷹ቯࠍⴕߞߚޕ
㧨ⵝ⟎㧪
☳ᧃ X✢᷹ቯⵝ⟎Mini Flex IIޔ࡝ࠟࠢ␠⵾
㧨᷹ቯ᧦ઙ㧪
Target : Cu 
Filter : Ni 
Voltage : 30 kv 
Current : 15 mA 
Scanning speed : 4 °/min 
Scanning angle : 2 㨪 35 ° 
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ṁ⸃ᐲ᷹ቯ
PG᳓ṁᶧਛߩ⮎‛ṁ⸃ᐲߩ᷹ቯࠍⴕߞߚޕㆊ೾㊂ߩ⮎‛ࠍฦỚᐲߩ PG᳓
ṁᶧߦട߃ޔ᳓ᶎਛ 32 °Cߢ 24ᤨ㑆ᝄ⋟ߒߚޕ⹜ᢱṁᶧࠍ 0.45 μmߩࡔࡦࡉ
࡜ࡦࡈࠖ࡞࠲࡯ߢࠈㆊᓟޔHPLCߦߡ⮎‛Ớᐲߩ᷹ቯࠍⴕߞߚޕ
㧨HPLCⵝ⟎㧪
ࡐࡦࡊ : L-6000 (ᣣ┙⵾૞ᚲ␠⵾)
UVᬌ಴ེ : L-4000 (ᣣ┙⵾૞ᚲ␠⵾)
ࠝ࡯࠻ࠨࡦࡊ࡜࡯ : AS-4000 (ᣣ┙⵾૞ᚲ␠⵾)
ࠞ࡜ࡓࠝ࡯ࡉࡦ : U-620 (ࠬࠟࠗࠤࡒ࡯␠⵾)
㧨ࡇࡠࠠࠪࠞࡓ᷹ቯ᧦ઙ㧪
ࠞ࡜ࡓ : ࠗ࠽࡯࠻ࠪ࡞ ODS-4 (4.6 mm i.d. u 250 mmޔ
☸ሶࠨࠗ࠭ 5 ȝm; GLࠨࠗࠛࡦࠬ␠⵾)
ࠟ࡯࠼ࠞ࡜ࡓ : L-column ODS (4.6 mm i.d. u 10 mmޔ
☸ሶࠨࠗ࠭ 5 ȝm㧧 ൻቇ‛⾰⹏ଔ⎇ⓥᯏ᭴␠⵾)
ࠞ࡜ࡓ᷷ᐲ : 40 r 0.5 °C 
ᵹㅦ : 1.0 mL/min 
UVᵄ㐳 : 365 nm 
⒖േ⋧ : ࠕ࠮࠻࠾࠻࡝࡞/0.01 M ㈶㉄࡮㈶㉄࠽࠻࡝࠙ࡓ✭ⴣᶧ
(pH 4.6) 35:65 v/v 
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㧨ࡊ࡜ࡁࡊࡠࡈࠚࡦ᷹ቯ᧦ઙ㧪
ࠞ࡜ࡓ : TSK Gel ODS-120T (4.6 mm i.d. u 150 mmޔ
☸ሶࠨࠗ࠭ 5 ȝm㧧 ᧲࠰࡯␠⵾)
ࠟ࡯࠼ࠞ࡜ࡓ : L-column ODS (4.6 mm i.d. u 10 mmޔ
☸ሶࠨࠗ࠭ 5 ȝm㧧 ൻቇ‛⾰⹏ଔ⎇ⓥᯏ᭴␠⵾)
ࠞ࡜ࡓ᷷ᐲ : 40 r 0.5 °C 
ᵹㅦ : 1.0 mL/min 
UVᵄ㐳 : 275 nm 
⒖േ⋧ : ࠕ࠮࠻࠾࠻࡝࡞/0.01 M㈶㉄࡮㈶㉄࠽࠻࡝࠙ࡓ✭ⴣᶧ
(pH 4.6) 25:75 v/v 
ಽ㈩ଥᢙ᷹ቯ
n-ࠝࠢ࠲ࡁ࡯࡞ߪ⫳⇐᳓ߢ㘻๺ߐߖޔ߹ߚ⫳⇐᳓ߪ n-ࠝࠢ࠲ࡁ࡯࡞ߢ㘻๺
ߐߖߚᓟޔ⹜㛎ߦ↪޿ߚޕn-ࠝࠢ࠲ࡁ࡯࡞෸߮ PG᳓ṁᶧࠍ૕ⓍᲧ 8:2ߢࠟ࡜
ࠬ⵾⹜㛎▤ߦ౉ࠇޔᦝߦㆡᒰ㊂ߩ⮎‛ࠍട߃ߚޕࠟ࡜ࠬ⵾⹜㛎▤ࠍ 32 °C ߩ
᳓ᶎਛߢ 24ᤨ㑆ᝄ⋟ߒޔߘߩᓟ 3000 rpmߢ 10ಽ㑆㆙ᔃಽ㔌ࠍⴕߞߚޕn-ࠝ
ࠢ࠲ࡁ࡯࡞෸߮ PG᳓ṁᶧߩฦ⹜ᢱṁᶧࠍណขߒޔHPLCߦߡ⮎‛Ớᐲߩ᷹ቯ
ࠍⴕߞߚޕ
㧨HPLCⵝ⟎㧪
ṁ⸃ᐲ᷹ቯߣห᭽ޕ
㧨ࡇࡠࠠࠪࠞࡓ᷹ቯ᧦ઙ㧪
ṁ⸃ᐲ᷹ቯߣห᭽ޕ
㧨ࡊ࡜ࡁࡊࡠࡈࠚࡦ᷹ቯ᧦ઙ㧪
ṁ⸃ᐲ᷹ቯߣห᭽ޕ
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In vitro皮膚透過性の測定 
すべての動物実験は、動物実験委員会 (千葉大学大学院薬学研究院及びエ
スエス製薬)で承認され、また『日本薬理学会承認実験動物の管理と使用に関
する原則』ガイドラインに従って実施した。頸部脱臼により屠殺したHos:HR-1
雄性ヘアレスマウス (7 ～ 8週齢、日本エスエルシー社製)の背部皮膚を摘出
した後、皮下に付着した脂肪組織及び他の内臓片を除去した。In vitro皮膚透
過性試験は、縦型フランツタイプ拡散セルを用いて 32 °C にて実施した。有
効拡散面積 3.14 cm2、リザーバーセル容量約 16.0 mLの拡散セルを用いた。試
料懸濁液は、0.5% w/vピロキシカムあるいは 1.0% w/vプラノプロフェンとな
るように各 GMを PG水溶液中に分散後、5分間超音波処理にて懸濁し、調製
した。試料懸濁液は、0.9 mLをドナー相へ適用した。リザーバー相には、4% 
w/vアルブミン含有リン酸緩衝生理食塩水 (改良 PBS； pH 7.4) 31)を使用し、
マグネチックスターラーにて 500 rpm で撹拌した。試料懸濁液を適用後、2、
4、6及び 8時間後にリザーバー相より試料溶液を 0.4 mLずつ採取し、同量の
改良 PBS を補充した。採取した試料溶液は、HPLC にて薬物濃度を測定し、
累積皮膚透過量を算出した。 
＜HPLC装置＞ 
溶解度測定と同様。 
＜ピロキシカム測定条件＞ 
溶解度測定と同様。 
＜プラノプロフェン測定条件＞ 
溶解度測定と同様。 
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ᴺᣇᨆ⸃࠲࡯࠺ )4(
ߡߒኻߦ㑆ᤨฦޔߪ㊂ㆊㅘ⤏⊹Ⓧ⚥ߩࡦࠚࡈࡠࡊࡁ࡜ࡊ߮෸ࡓࠞࠪࠠࡠࡇ
ߒ಴▚ࠍ xulf ߔ⴫ࠍᐲㅦㆊㅘ⤏⊹ࠄ߆߈௑ߩಽㇱ✢⋥ߚࠇࠄᓧޔߒ࠻࠶ࡠࡊ
࠻ࡦ࠺࡯ࡘ࠴ࠬޔᓟߚߞⴕࠍቯᬌ Fޔߪଔ⹏⊛ቇ⸘⛔ߩ࠲࡯࠺ߚࠇࠄᓧޕߚ
ߞⴕߡߦ)ᢔಽ╬㕖( ቯᬌ t ߩ࠴࡞ࠚ࠙́ࡦࡇࠬࠕߪ޿ࠆ޽)ᢔಽ╬( ቯᬌ t ߩ
ޕߚ
ᴺᣇኤⷰ❱⚵ )5(
㑆ᤨ42 ߡߦࡦ࡝ࡑ࡞ࡎⴣ✭ᕈਛ%01 ࠍ⤏⊹ㇱ⢛ߚߒ಴៰ޔߪኤⷰ⊛ቇ❱⚵
ߦᴺᏱߡߒߣ ಾߩmμ 3ޔᓟߚߒၒ൮ࡦࠖࡈ࡜ࡄ߮෸᳓⣕ߦᦝޔߒቯ࿕ẃᶐ
శⰯޔߪ ಾ❱⚵ߚߒᚑ૞ޕߚߞⴕࠍ⦡ᨴࡦࠪࠝࠛ࡮ࡦ࡝ࠪࠠ࠻ࡑࡋߡߞᓥ
ޕߚߒኤⷰߡߦ)⵾␠ࠬࡦࠛ࡯ࠠ( 0018-ZB orezoiB ㏜ᓸ㗼
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╙ 1▵ ࠽ࡁᓸ☸ሶൻߦㆡߒߚ᳓ṁᕈ㜞ಽሶߩࠬࠢ࡝࡯࠾ࡦࠣ
෸߮☳⎈ᤨ㑆ߩᦨㆡൻ
1-1 ᳓ṁᕈ㜞ಽሶߩࠬࠢ࡝࡯࠾ࡦࠣ
ᄖ↪೷ߣߒߡ৻⥸⊛ߦ૶↪ߐࠇߡ޿ࠆ᳓ṁᕈ㜞ಽሶߩ߁ߜޔPVP એᄖߢ⚻
⊹ๆ෼ታ㛎ߦㆡߒߚ߽ߩࠍㆬᛯߔࠆߚ߼ޔ⮎‛ (ࡇࡠࠠࠪࠞࡓޔࡊ࡜ࡁࡊࡠ
ࡈࠚࡦ)ޔฦ⒳᳓ṁᕈ㜞ಽሶ෸߮⇇㕙ᵴᕈ೷ SDSߩ 3ᚑಽᷙว☳⎈ߦࠃࠅᓧࠄ
ࠇࠆ GM Ộᶧߩ☸ሶᓘࠍ⹏ଔߒߚ (Table 1)ޕ6⒳㘃ߩ᳓ṁᕈ㜞ಽሶࠍ↪޿
ߚ႐วߩ☸ሶᓘࠍᲧセߒߚ⚿ᨐޔHPMC ࠍ↪޿ࠆߎߣߢࡇࡠࠠࠪࠞࡓ෸߮ࡊ
࡜ࡁࡊࡠࡈࠚࡦߣ߽ߦ☸ሶᓘ߇ 200 nm એਅࠍ␜ߒޔਔ⮎‛ߦኻߒߡ HPMC
ߣߩᷙว☳⎈߇࠽ࡁᓸ☸ሶൻߦ᦭ലߢ޽ࠆߎߣ߇᣿ࠄ߆ߣߥߞߚޕ
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Table 1  Mean particle size of piroxicam and pranoprofen 
prepared by ternary components grinding.
 Mean particle size (nm) 
piroxicam/HEC/SDS a 779 r 98 
piroxicam/HPC/SDS b 699 r 49 
piroxicam/HM-HPMC/SDS a 481 r 57 
piroxicam/HPMC/SDS a 103 r 4 
piroxicam/PGA/SDS a 258 r 28 
piroxicam/PVA/SDS b 848 r 50 
pranoprofen/HEC/SDS a 1197 r 682 
pranoprofen/HPC/SDS b 663 r 176 
pranoprofen/HM-HPMC/SDS a 666 r 43 
pranoprofen/HPMC/SDS a 175 r 6 
pranoprofen/PGA/SDS a 284 r 19 
pranoprofen/PVA/SDS b 862 r 132 
a  Samples were prepared by grinding of PM at room 
temperature for 60 min. 
b  Samples were prepared by grinding of PM at í180 qC
for 60 min. 
Each value represents the mean r S.D. (n = 3). 
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ൻㆡᦨߩ㑆ᤨ⎈☳ 2-1
ᦨޔߡ޿߅ߦ⎈☳วᷙಽᚑ3 ߚ޿↪ࠍCMPH ߚࠇߐ⹺⏕߇ᚑᒻሶ☸ᓸࡁ࠽
ޔߪߢMG SDS/CMPH/ࡓࠞࠪࠠࡠࡇޕ)2 elbaT( ߚߞⴕࠍ⸛ᬌߩ㑆ᤨ⎈☳ߥㆡ
ࠇߙࠇߘߪᓘሶ☸ဋᐔߩ MG ฦߩಽ 042 ߮෸ 081ޔ021ޔ09ޔ06 ߇㑆ᤨ⎈☳
߅ߦ㑆ᤨ⎈☳ߩ਄એಽ09ޔࠅߥߣmn 96 ߮෸mn 86ޔmn 17ޔmn 67ޔmn 101
ࡓࠞࠪࠠࡠࡇޔࠄ߆ߣߎߩߎޕߚߒ᧤෼ߦ୯ߩᓟ೨mn 07 ߪᓘሶ☸ဋᐔߡ޿
SDS/CMPH/ࡦࠚࡈࡠࡊࡁ࡜ࡊޕߚࠇࠄ߃⠨ߣࠆ޽ߢㆡᦨ߇ಽ09 ߪ㑆ᤨ⎈☳ߩ
ߪᓘሶ☸ဋᐔߩMG ฦߩಽ042 ߮෸081ޔ021ޔ09ޔ06 ߇㑆ᤨ⎈☳ޔߪߢMG
021 ߮෸09ޔࠅߥߣmn 352 ߮෸mn 103ޔmn 641ޔmn 641ޔmn 561 ࠇߙࠇߘ
߇㑆ᤨ⎈☳ߣಽ042ޔ081ޕߚߞߥߣዊᦨ߇ᓘሶ☸ဋᐔߡ޿߅ߦ㑆ᤨ⎈☳ߩಽ
ߣߎߚߞߥߊ߈ᄢߦㅒ߇࠭ࠗࠨሶ☸ߣ਄એ mn 052 ߇ᓘሶ☸ဋᐔߣࠆߥߊ㐳
ޕߚࠇࠄ߃⠨ߣࠆ޽ߢㆡᦨ߇ಽ09 ߪ㑆ᤨ⎈☳ߩࡦࠚࡈࡠࡊࡁ࡜ࡊޔࠄ߆
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Table 2  Effect of grinding time on mean particle size of piroxicam or 
pranoprofen prepared by drug/HPMC/SDS ternary components grind-
ing.
 60 min 90 min 120 min 180 min 240 min 
piroxicam 101 r 3 76 r 3 71 r 4 68 r 1 69 r 1
pranoprofen 165 r 6 146 r 3 146 r 6 301 r 121 253 r 95
Mean particle size (nm) 
Each value represents the mean r S.D. (n = 3).
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1-3 PG᳓ṁᶧਛߢߩ࠽ࡁᓸ☸ሶߩ቟ቯᕈ⹏ଔ
⊹⤏ㅘㆊᕈ⹜㛎ࠍታᣉߔࠆ೨ߦޔฦỚᐲߩ PG ᳓ṁᶧਛߦ߅ߌࠆ⮎‛☸ሶ
ࠨࠗ࠭ߩ⚻ᤨ⊛ߥ቟ቯᕈࠍ⏕⹺ߒߚ (Fig. 1)ޕࡇࡠࠠࠪࠞࡓ/HPMC/SDS GM 
(Fig. 4a)෸߮ࡊ࡜ࡁࡊࡠࡈࠚࡦ/HPMC/SDS GM (Fig. 4b)ߩ⮎‛☸ሶࠨࠗ࠭ࠍ
ฦỚᐲߩ PG ᳓ṁᶧਛߢᬌ⸛ߒߚ⚿ᨐޔ8 ᤨ㑆߹ߢᐔဋ☸ሶᓘߦᄌൻ߇ߥߊޔ
቟ቯߢ޽ߞߚޕߎࠇࠄߩ⚿ᨐߪޔWanawongthai ࠄ߇ࡊࡠࡉࠦ࡯࡞/PVP/SDS
ߩ 3ᚑಽ♽ࠍ↪޿ߡႎ๔ߒߚ⚿ᨐࠍᡰᜬߔࠆ߽ߩߢ޽ߞߚ 32)ޕᓐࠄߪޔ᳓ṁ
ᶧਛߢ↢ᚑߒߚ PVṔ⇇㕙ᵴᕈ೷ⶄว૕߇ࡊࡠࡉࠦ࡯࡞࠽ࡁᓸ☸ሶߩ⴫㕙ࠍ
ቢోߦⷒ߁ߎߣߦࠃߞߡޔ⮎‛☸ሶߩㅦ߿߆ߥಝ㓸ࠍ㒐޿ߢ޿ࠆߣㅀߴߡ޿
ࠆޕࡇࡠࠠࠪࠞࡓ/HPMC/SDS ෸߮ࡊ࡜ࡁࡊࡠࡈࠚࡦ/HPMC/SDS ߩ႐ว߽ޔ
᳓ṁᶧਛߢ↢ᚑߒߚ HPMC-SDS ⶄว૕߇ฦ⮎‛࠽ࡁᓸ☸ሶߩ⴫㕙ࠍቢోߦ
ⷒߞߚߣផ᷹ߐࠇߚޕ
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Fig. 4.  Changes in mean particle size of (a) piroxicam/HPMC/SDS and 
(b) pranoprofen/HPMC/SDS ternary GMs in PG aqueous solution at 
32 °C. Weight ratio of drug/HPMC/SDS was 1/3/1. 
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ଔ⹏ߩᕈㆊㅘ⤏⊹ ▵2 ╙
㗀ᓇߩൻሶ☸ᓸࡁ࠽ 1-2
ޔ߼ߚࠆߔଔ⹏ࠍᕈㆊㅘ⤏⊹ߩࡓࠞࠪࠠࡠࡇߩࠄ߆MGಽᚑ3 ࡓࠞࠪࠠࡠࡇ
ߔ␜ߦd–a5 .giFޕ)5 .giF( ߚߒセᲧࠍ㊂ㆊㅘ⤏⊹Ⓧ⚥ߩߣMP ߩᚑ⚵หߦೋᦨ
⚥ߩࡓࠞࠪࠠࡠࡇߩࠄ߆ MG ߽ߡ޿߅ߦਛᶧṁ᳓ GP ߩᐲỚߩࠇߕ޿ޔࠅㅢ
ࠪࠠࡠࡇޕߚߞߥߣ߆ࠄ᣿߇ߣߎ޿㜞ߦᗧ᦭ߡߒセᲧߣMPޔߪ㊂ㆊㅘ⤏⊹Ⓧ
ࠇߐኤផߣߚߒਈነߦㅴ੣ᕈㆊㅘ⤏⊹߇ߣߎࠆ޿ߡࠇߐൻሶ☸ᓸࡁ࠽߇ࡓࠞ
Ⓧ⚥ߩߣ MP ߣ MG ߦ᭽หߣࡓࠞࠪࠠࡠࡇ߽ߡ޿߅ߦࡦࠚࡈࡠࡊࡁ࡜ࡊޕߚ
MG ߽ߡ޿߅ߦਛᶧṁ᳓ GP ߩᐲỚߩࠇߕ޿ޔࠈߎߣߚߒセᲧࠍ㊂ㆊㅘ⤏⊹
ߚߞ߆㜞ߦᗧ᦭ߡߒセᲧߣMPޔߪ㊂ㆊㅘ⤏⊹Ⓧ⚥ߩࡦࠚࡈࡠࡊࡁ࡜ࡊߩࠄ߆
ޕ)6 .giF(
ޕࠆ޽߇๔ႎߩ߆ߟߊ޿ޔߪߡ޿ߟߦ㗀ᓇߩ࠭ࠗࠨሶ☸ࠆߔኻߦᕈㆊㅘ⤏⊹
࠭ࠗࠨሶ☸ࠆߥ⇣ߩmn 0051ޔmn 057ޔmn 04 ࠆߔ᦭฽ࠍ⾰‛శⰯޔߪࠄtgoV
ߢⓣᲫߪ࠻࡯࡞ㆊㅘߩ‛⮎ሶ☸ᓸࡁ࠽ޕ)82 ߚߒ⸛ᬌࠍᕈㆊㅘ⤏⊹ߩሶ☸ᓸߩ
ߦᦝޕࠆ޿ߡߒߣࠆ߈ߢ㆐ㅍ߳ጀ⊹⴫߇ߺߩሶ☸ᓸࡁ࠽ߩ mn 04ޔࠅ޽
ࡐᕈ⸃ಽ↢㕖ߩmn 002 ߮෸mn 02 ࠆߔ᦭฽ࠍ⾰‛శⰯޔߪࠄnámoR-zeravlA
ࠗࠨሶ☸ޕ)72 ߚߒଔ⹏ࠍᕈㆊㅘߩ߳⤏⊹⽋ޔߡ޿↪ࠍሶ☸ᓸࡁ࠽ࡦ࡟࠴ࠬ࡝
⤏⊹ߦᓟಽ03 ߆ߕࠊᓟ↪ㆡޔ߈ߣߚߒ↪ㆡࠍሶ☸ᓸࡁ࠽ߩmn 02 ޿ߐዊߩ࠭
ߒ࿷ሽ߆ߒ%1.0 㨪߆ߕࠊߩⓍ㕙⴫૕⤏⊹ߪⓣᲫޔ߇ࠆߔⓍ㓸ߦⓣᲫ߮෸㕙⴫
ࠇߐⷞή߫ߒ߫ߒߪਈነߩ〝⚻ߩߎࠆߔኻߦ૕ోⴕ⒖ਛ⤏⊹ޔࠄ߆ߣߎ޿ߥ
ߩߩ߽ߩߘሶ☸ᓸࡁ࠽ߪߦㅴଦᕈㆊㅘ⤏⊹ߩ⾰‛శⰯᕈṁ⢽ޔ߼ߚߩߘޕࠆ
ߣࠆ޿ߡߒㅪ㑐߇಴᡼ߥ⊛ᨐലߩ⾰‛శⰯߩࠄ߆ሶ☸ᓸࡁ࠽ޔߊߥߪߢㆊㅘ
ߚࠇߐ⵾⺞ࠅࠃߦ⎈☳วᷙߩߣSDS ߮෸21K PVPޔߪࠄebiroMޕࠆ޿ߡߴㅀ
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Fig. 5.  Amount of piroxicam permeated from piroxicam/HPMC/SDS 
PMs and GMs in (a) distilled water, (b) 10% PG aqueous solution, (c) 
30% PG aqueous solution, and (d) 50% PG aqueous solution at 32 °C. 
Weight ratio of piroxicam/HPMC/SDS was 1/3/1. Each point represents 
the mean ± S.D. (n = 4). **: p < 0.01. 
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Fig. 6.  Amount of pranoprofen permeated from pranoprofen/HPMC/ 
SDS PMs and GMs in (a) distilled water, (b) 10% PG aqueous solution, 
(c) 30% PG aqueous solution, and (d) 50% PG aqueous solution at 32 °C. 
Weight ratio of pranoprofen/HPMC/SDS was 1/3/1. Each point 
represents the mean ± S.D. (n = 3 ∼ 4). *: p < 0.05, **: p < 0.01. 
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2-2 ☳⎈⚵ᚑߩᓇ㗀
ࡇࡠࠠࠪࠞࡓߩ⊹⤏ㅘㆊᕈߦ෸߷ߔ☳⎈⚵ᚑߩᓇ㗀ࠍᬌ⸛ߔࠆߚ߼ޔࡇࡠ
ࠠࠪࠞࡓ/HPMC 2ᚑಽGM (⚵ᚑᲧ 1/3)ߣࡇࡠࠠࠪࠞࡓ/HPMC/SDS 3ᚑಽGM 
(⚵ᚑᲧ 1/3/1)ߩ⊹⤏ㅘㆊᕈࠍᲧセߒߚ (Fig. 7a)ޕPXRD ᷹ቯߩ⚿ᨐࠃࠅޔࡇ
ࡠࠠࠪࠞࡓ/HPMC GM ෸߮ࡇࡠࠠࠪࠞࡓ/HPMC/SDS GM ਛߩฦࡇࡠࠠࠪࠞ
ࡓߪ⚿᥏ߣߒߡሽ࿷ߒߡ޿ߚ (Fig. 8)ޕࡇࡠࠠࠪࠞࡓ/HPMC/SDS GMߪޔࡇ
ࡠࠠࠪࠞࡓ/HPMC GMߣᲧセߒߡ☸ሶᓘߦᄢ߈ߥᏅߪߥ޿߇ޔ⫳⇐᳓ࠍ↪޿
ߚ♽ߢߩࡇࡠࠠࠪࠞࡓ/HPMC/SDS GM ߩ⚥Ⓧ⊹⤏ㅘㆊ㊂ߪࡇࡠࠠࠪࠞࡓ
/HPMC GMߣᲧセߒߡޔ᦭ᗧߦ㜞޿ߎߣ߇⹺߼ࠄࠇߚޕߘߩߚ߼ޔᷙว☳⎈
⚵ᚑ߇ 2ᚑಽ(ࡇࡠࠠࠪࠞࡓ෸߮ HPMC)ߢߪߥߊޔ3ᚑಽߢ޽ࠆߎߣ߇⊹⤏ㅘ
ㆊᕈ੣ㅴߦኻߒߡ㊀ⷐߥⷐ࿃ߢ޽ࠆߎߣ߇᣿ࠄ߆ߣߥߞߚޕMoribe ࠄߪޔࡇ
ࡠࠠࠪࠞࡓ߇⚿᥏⁁ᘒߢሽ࿷ߔࠆࡇࡠࠠࠪࠞࡓ/PVP K12/SDS 3ᚑಽ GM (⾰
㊂Ყ 1/3/1)ߣ㕖᥏⾰⁁ᘒߢሽ࿷ߔࠆࡇࡠࠠࠪࠞࡓ/PVP K12 2ᚑಽ GM (⾰㊂Ყ
1/3)ߩࡋࠕ࡟ࠬࡑ࠙ࠬߦ߅ߌࠆ⊹⤏ㅘㆊᕈࠍᲧセߒߚ 30)ޕᓐࠄߪޔ3ᚑಽ GM
ߪ 2ᚑಽ GMߣᲧセߒߡ᦭ᗧߦ⚥Ⓧ⊹⤏ㅘㆊ㊂߇㜞޿ߎߣࠍ⷗಴ߒߚޕ⚿⺰
ߣߒߡޔࡇࡠࠠࠪࠞࡓߩ⊹⤏ㅘㆊᕈ੣ㅴ߇ࡇࡠࠠࠪࠞࡓಽሶߩಽᢔ⁁ᘒߦࠃ
ࠆ߽ߩߢߪߥߊޔ࠽ࡁᓸ☸ሶൻ (ᐔဋ☸ሶᓘ 23 nm)ߦࠃࠆലᨐߢ޽ࠆߣㅀߴ
ߡ޿ࠆޕ
ࡇࡠࠠࠪࠞࡓ/SDS GM (⚵ᚑᲧ 1/1)ߣࡇࡠࠠࠪࠞࡓ/HPMC/SDS GMߩ⊹⤏
ㅘㆊᕈࠍᲧセ⹏ଔߒߚ (Fig. 7b)ޕߘߩ⚿ᨐޔࡇࡠࠠࠪࠞࡓ/SDS GMߩ⚥Ⓧ⊹
⤏ㅘㆊ㊂ߪࡇࡠࠠࠪࠞࡓ/HPMC/SDS GM ߣᲧセߒߡ⪺ߒߊ㜞޿୯ࠍ␜ߒߚޕ
⚵ᚑߦࠃࠅ⊹⤏ㅘㆊᕈ߇⪺ߒߊ⇣ߥࠆේ࿃ߣߒߡޔSDS ߩ⊹⤏㓚ኂᕈ߇⠨߃
ࠄࠇߚޕߘߎߢޔ⊹⤏ㅘㆊᕈ⹜㛎 8 ᤨ㑆ᓟߩࡋࠕ࡟ࠬࡑ࠙ࠬ⢛ㇱ⊹⤏ࠍ HE
ᨴ⦡ಣℂߒߚᓟޔ㗼ᓸ㏜ߦߡⷰኤߒߚ (Fig. 9)ޕߘߩ⚿ᨐޔFig. 9bߦ␜ߒߚㅢ
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ޔߕߖ࿷ሽߤࠎߣ߶߇ጀ⾰ ⷺޔߪߢ⤏⊹ߚߒ↪ㆡࠍMG SDS/ࡓࠞࠪࠠࡠࡇޔࠅ
ߎࠆߔ᦭ࠍᕈỗೝ⤏⊹ߪ SDSޕߚࠇߐ⹺⏕߽ᱫუߩ⢩⚦⊹⌀ޔߒ㔌೸߽⊹⴫
㓚⤏⊹ࠆࠃߦSDS ߽ᨐ⚿ߩ࿁੹ޔ)33 ࠅ߅ߡࠇߐ๔ႎߡߞࠃߦࠄshtiffirG ߇ߣ
⊹ߚߒ↪ㆡࠍMG SDS/CMPH/ࡓࠞࠪࠠࡠࡇޔᣇ৻ޕࠆࠇࠄ߃⠨ߣᨐ⚿ߩᕈኂ
ߎࠆ޽ߢ╬ห߷߶ߣ)c9 .giF( ⤏⊹ߥᏱᱜ޿ߥ޿ߡ޿↪ߦ㛎⹜ޔߪ)a9 .giF( ⤏
ޕߚߞ߆ߥߐ␜ࠍᕈኂ㓚⤏⊹ࠆࠃߦSDSߥ߁ࠃߩᤨ⎈☳ಽᚑ2ޔࠇߐ⹺⏕߇ߣ
ޔ)23 ࠅ߅ߡࠇࠄ⍮߇ߣߎࠆߔᚑᒻࠍ૕วⶄߣPVPߦᤨ⎈☳วᷙಽᚑ3ߪSDS
nossliNޕࠆࠇࠄ߃⠨ߣࠆߔ㗀ᓇߦ↪૞ᕈᵴ㕙⇇ߩ SDS ߩᓟᢔಽߦ᳓߇ࠇߘ
ߣߎࠆߎ⿠߇↪૞੕⋧ߡߒሽଐߦᐲỚߩ CMPH ߦᤨ࿷ሽ CMPH ߪ SDSޔߪ
▸ᐲỚߣᚑ⚵ߩ࿐▸ᐢޔߡ޿ߟߦ♽ߩ retaw/SDS/CMPHޕ)43 ࠆ޿ߡߒ๔ႎࠍ
ᐔߩജ⢻⌕ๆᄢᦨࠆߔኻߦ㎮ሶಽ㜞ޔߪᓐޕࠆ޿ߡࠇࠊⴕ߇ଔ⹏ࠆߔኻߦ࿐
ޕࠆ޿ߡߒ๔ႎߣࠆߔ⌕ๆᐲ⒟1 ࠍSDS ߷߶ߡߒኻߦ૏න࡯ࡑࡁࡕሶಽ㜞ߪဋ
2.0 ߪ㊂⌕ๆߩSDS ࠆߔኻߦ૏නࠬ࡯ࠦ࡞ࠣߩCMPHޔߪߡ޿߅ߦ㛎ታߩ࿁੹
ߢߣߎߚߒᚑᒻࠍ૕วⶄߒ↪૞੕⋧߇SDS ߣCMPHޔߡߞᓥޕࠆࠇߐ಴▚ߣ
ޕߚࠇߐኤផߣߚߖߐᒙᷫࠍኂ㓚⤏⊹ࠆࠃߦSDS
ࡦࠚࡈࡠࡊࡁ࡜ࡊޔࠍ㗀ᓇߩᚑ⚵ߔ߷෸ߦㆊㅘ⤏⊹ߩࡦࠚࡈࡠࡊࡁ࡜ࡊ
⚵( MG ಽᚑ3 SDS/CMPH/ࡦࠚࡈࡠࡊࡁ࡜ࡊߣ)3/1 Ყᚑ⚵( MG ಽᚑ2 CMPH/
ᓘሶ☸ߩMG CMPH/ࡦࠚࡈࡠࡊࡁ࡜ࡊޕ)c7 .giF( ߚߒ⸛ᬌセᲧߢ)1/3/1 Ყᚑ
ᄢ୚5.7 ⚂ߡߒセᲧߣMG SDS/CMPH/ࡦࠚࡈࡠࡊࡁ࡜ࡊޔࠅ޽ߢmμ 90.1 ߪ
᥏㕖ߪࡦࠚࡈࡠࡊࡁ࡜ࡊߩਛMG CMPH/ࡦࠚࡈࡠࡊࡁ࡜ࡊޔߚ߹ޕߚߞ߆߈
ࡦࠚࡈࡠࡊࡁ࡜ࡊߩਛMG SDS/CMPH/ࡦࠚࡈࡠࡊࡁ࡜ࡊޔߒኻߦߩࠆ޽ߢ⾰
ࡦࠚࡈࡠࡊࡁ࡜ࡊߩߢ᳓⇐⫳ޕ)01 .giF( ߚ޿ߡߒ࿷ሽߡߒߣ᥏⚿ㇱ৻ߪ
ߒセᲧߣMG CMPH/ࡦࠚࡈࡠࡊࡁ࡜ࡊޔߪ㊂ㆊㅘ⤏⊹Ⓧ⚥ߩMG SDS/CMPH/
ࡈࡠࡊࡁ࡜ࡊ߇ㅴ੣ᕈㆊㅘ⤏⊹ߩࡦࠚࡈࡠࡊࡁ࡜ࡊޔࠄ߆ߣߎ޿㜞ߦᗧ᦭ߡ
⠨ߣࠆ޽ߢᨐലࠆࠃߦൻሶ☸ᓸࡁ࠽ޔߊߥߪߢᨐലࠆࠃߦᘒ⁁⾰᥏㕖ߩࡦࠚ
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Fig. 7.  Effect of grinding composition on amount of piroxicam and 
pranoprofen permeated from binary (open circle) and ternary (closed cir-
cle) GMs dispersed in distilled water at 32 °C: (a) piroxicam/HPMC and 
piroxicam/HPMC/SDS, (b) piroxicam/SDS and piroxicam/HPMC/SDS, 
and (c) pranoprofen/HPMC and pranoprofen/HPMC/SDS. Weight ratio 
of drug/HPMC and drug/SDS was 1/3 and 1/1, respectively. Each point 
represents the mean ± S.D. (n = 3 ~ 4). *: p < 0.05, **: p < 0.01. 
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Fig. 8.  PXRD patterns of the piroxicam/HPMC/SDS system. 
(a) Unprocessed piroxicam, (b) HPMC, (c) SDS, (d) PM, (e) GM, (f) 
piroxicam/HPMC GM (1/3, w/w; 90 min grinding), and (g) piroxicam/ 
SDS GM (1/1, w/w; 90 min grinding). Piroxicam (▲), SDS (●). 
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Fig. 9.  Histological sections of hairless mouse skin stained with 
hematoxylin and eosin at 8 h after application of (a) piroxicam/ 
HPMC/SDS, (b) piroxicam/SDS GMs in distilled water, and (c) un-
treated skin. Weight ratio of piroxicam/SDS was 1/1. The stratum cor-
neum appears at the top with a red stain. Viable epidermis is immediately 
below with characteristic blue staining of epidermal cell nuclei. The 
pink-stained dermis is below the epidermis. Stratum corneum: SC, Via-
ble epidermis: VE, Dermis: D. 
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Fig. 10.  PXRD patterns of the pranoprofen/HPMC/SDS system. 
(a) Unprocessed pranoprofen, (b) HPMC, (c) SDS, (d) PM, (e) GM, (f) 
pranoprofen/HPMC GM (1/3, w/w; 90 min grinding), and (g) pranopro-
fen/SDS GM (1/1, w/w; 90 min grinding). Pranoprofen (■), SDS (●). 
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2-3 PG᳓ṁᶧߩᓇ㗀
Fig. 5ߩ a–dߩ⚿ᨐࠍᲧセߔࠆߣޔࡇࡠࠠࠪࠞࡓ 3ᚑಽ GMߩ PG᳓ṁᶧਛ
߆ࠄߩࡇࡠࠠࠪࠞࡓ⚥Ⓧ⊹⤏ㅘㆊ㊂ߪޔPGỚᐲߦଐሽߒߥ޿ߎߣ߇᣿ࠄ߆ߣ
ߥߞߚޕ৻ᣇޔࡊ࡜ࡁࡊࡠࡈࠚࡦߢߪ 3ᚑಽ GMߩ⚥Ⓧ⊹⤏ㅘㆊ㊂ߪޔPGỚ
ᐲჇടߦᓥ޿Ⴧടߔࠆߎߣ߇᣿ࠄ߆ߣߥߞߚ (Fig. 6)ޕࡇࡠࠠࠪࠞࡓ෸߮ࡊ࡜
ࡁࡊࡠࡈࠚࡦߘࠇߙࠇߩ⚵ᚑߦߟ޿ߡޔߎࠇ߹ߢߦᓧߚ⚥Ⓧ⊹⤏ㅘㆊ㊂ߩ࠺
࡯࠲߆ࠄ fluxࠍ▚಴ߒ Fig. 11ߦ߹ߣ߼ߚޕFig. 11aߦ␜ߒߚㅢࠅޔ࠽ࡁᓸ☸
ሶߢ޽ࠆࡇࡠࠠࠪࠞࡓ/HPMC/SDS GM߆ࠄߩࡋࠕ࡟ࠬࡑ࠙ࠬ⢛ㇱ⊹⤏ߦኻߔ
ࠆࡇࡠࠠࠪࠞࡓߩ flux ߪޔࡇࡠࠠࠪࠞࡓ/HPMC GM ޽ࠆ޿ߪࡇࡠࠠࠪࠞࡓ
/HPMC/SDS PMߩ fluxߣᲧセߒߡ᦭ᗧߦ㜞޿ߎߣ߇᣿ࠄ߆ߣߥߞߚޕᦝߦࡇ
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Fig. 11.  Skin permeation parameters of (a) piroxicam and (b) pranopro-
fen from drug/HPMC/SDS GM, drug/HPMC GM, and drug/HPMC/ 
SDS PM in PG aqueous solution at 32 °C. Each point represents the 
mean ± S.D. (n = 3 ~ 4). *: p < 0.05, **: p < 0.01. 
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Fig. 12.  Solubility (C: closed symbol) and partition coefficient (Log K: 
open symbol) of piroxicam (circle) and pranoprofen (square) in PG 
aqueous solution at 32 °C. Each point represents the mean ± S.D. (n = 3). 
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ABSTRACT 
The effects of water-soluble polymers on nanoparticle formation of piroxicam and 
pranoprofen were investigated.  We also studied the effects of propylene glycol (PG) 
concentration in PG aqueous solution on skin permeation of the drugs from nanopar-
ticles.  Physical mixtures (PMs) of the drug, hydroxypropylmethylcellulose (HPMC), 
and sodium dodecyl sulfate (SDS) (weight ratio, 1:3:1) were ground for 90 min in a 
vibrational rod mill to prepare ground mixtures (GMs).  The particle sizes of the 
GM suspensions in distilled water were 76 nm for piroxicam and 146 nm for 
pranoprofen, respectively.  It was found that the permeation of piroxicam and 
pranoprofen through hairless mouse skin was significantly increased when the ter-
nary GMs were suspended in PG aqueous solution; however, no enhanced permea-
tion was observed with drug/HPMC binary GMs.  Because the piroxicam/SDS bi-
nary GM caused skin damage, a ternary GM was critical for increasing the skin 
permeation of poorly water-soluble drugs.  The skin permeation of piroxicam and 
pranoprofen could be attributed to their supersaturation in suspension due to 
nanoparticle formation.  The skin permeation of piroxicam from the GM suspension 
was independent of PG concentration in PG aqueous solution, but that of pranopro-
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fen increased with PG concentration in PG aqueous solution.  This difference can 
be attributed to the different solubilities of piroxicam and pranoprofen in PG 
aqueous solution. 
Key words:  
Skin permeation 
Piroxicam 
Pranoprofen 
Cogrinding
Nanoparticle
Abbreviations: DEET, N,N-diethyl-m-toluamide; GM, ground mixture; HEC, 
hydroxyethylcellulose; HPC, hydroxypropylcellulose; HPLC, high-performance
liquid chromatography; HM-HPMC, hydrophobically modified hydroxypro-
pylmethylcellulose; HPMC, hydroxypropylmethylcellulose; PBS, phosphate 
-buffered saline; PG, propylene glycol; PGA, propylene glycol alginate; PM, physical 
mixture; PVA, polyvinyl alcohol; PVP, polyvinylpyrrolidone; SDS, sodium dodecyl 
sulfate
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Reduction in the particle size of hydrophobic drugs has attracted interest with re-
gard to improving their dissolution and absorption properties [1-5].  Grinding is one 
method used to reduce the size of drug crystals.  Cogrinding of a hydrophobic drug 
with a water-soluble polymer and surfactant is effective for nanoparticle formation of 
the drug [6-9].  For example, probucol particles of about 72 nm were formed by 
cogrinding probucol/methacrylic acid-methylmethacrylate copolymer/sodium do-
decyl sulfate (SDS) in a weight ratio of 1:5:1 [9].  Oral administration of coground 
nanoparticles (about 28 nm) of probucol/polyvinylpyrrolidone (PVP) K12/SDS as a 
suspension to rats resulted in markedly increased plasma levels of the drug with 
decreasing particle size [8]. 
Nanoparticle drugs have been examined for oral [10, 11], mucosal [12, 13], 
subcutaneous [14, 15], and transdermal administration [16, 17].  Transdermal 
administration has advantages such as prevention of the first-pass effects on 
gastrointestinal absorption, maintenance of the steady state of the in vivo drug 
concentration, prevention of gastrointestinal damage, easy discontinuance if side 
effects develop, and improved compliance by reduced frequency of administration.  
Improved drug absorption via the transdermal route was possible by enhancing skin 
permeation using chemical modification and salt exchange of a drug molecule 
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[18-20], drug complex formation with excipients such as cyclodextrin [21-23], or use 
of a permeation enhancer [24-26].  Recently, the use of nanoparticles for enhancing 
transdermal absorption has been reported [27-30].  Alvarez-Román et al. [27] ex-
amined the skin permeation of a lipophilic fluorescent material, contained in 
non-biodegradable polystyrene nanoparticles, to demonstrate enhanced skin permea-
tion through rapid accumulation of nanoparticles (20 nm) in hair follicles.  Further, 
Vogt et al. [28] and Tsujimoto et al. [29] reported that the skin permeation of 
nanoparticles was enhanced through hair follicles.  In a permeation study of hairless 
mouse skin with fewer hair follicles and other dermal appendages, Moribe et al. [30] 
reported that drug absorption increases as the effect of particle size decreases.  
However, they derived the results by using only PVP, and not other water-soluble 
polymers as external preparations.  Therefore, the effects of cogrinding composi-
tions and components of a dispersion medium on the skin permeation of nanoparticle 
drugs should be further examined. 
The aims of this study were to investigate nanoparticle formation of ternary 
ground mixtures (GMs), namely, a drug, water-soluble polymer, and SDS, by using 
piroxicam and pranoprofen, non-steroidal anti-inflammatory drugs with similar ef-
fects as model drugs; identify the suitability of various water-soluble polymers 
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(excluding PVP) generally used as external preparations for piroxicam and pranopro-
fen nanoparticle formation; and examine the effects of compositions of the resulting 
piroxicam and pranoprofen nanoparticle suspensions in a dispersion medium on in
vitro skin permeation. 
I. MATERIALS AND METHODS 
1. Materials
Piroxicam and pranoprofen were purchased from Wako Pure Chemical Industries 
Ltd. (Osaka, Japan) and API Corporation (Osaka, Japan), respectively.  The 
water-soluble polymers used in this study were hydroxyethylcellulose (HEC CF-G; 
HEC) and hydroxypropylcellulose (HPC-L; HPC), obtained from Sumitomo Seika 
Chemicals Co., Ltd. (Osaka, Japan) and Nippon Soda Co., Ltd. (Tokyo, Japan), 
respectively; hydrophobically modified hydroxypropylmethylcellulose (Sangelose
60L; HM-HPMC), supplied by Daido Chemical Industry Co., Ltd. (Osaka, Japan); 
hydroxypropylmethylcellulose type 2910 (TC-5E; HPMC), purchased from 
Shin-Etsu Chemical Co., Ltd. (Tokyo, Japan); propylene glycol alginate (Duckloid 
SLF-3; PGA), obtained from Kikkoman Biochemifa Company (Chiba, Japan); and 
polyvinyl alcohol (Gohsenol EG-05PW; PVA), supplied by Nippon Synthetic 
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Chemical Industry Co., Ltd. (Osaka, Japan).  SDS, an anionic surfactant, was pur-
chased from Wako Pure Chemical Industries Ltd.  Isoxicam and sulindac, used as 
internal standards for high-performance liquid chromatography (HPLC) analy-
sis, were obtained from Sigma-Aldrich Japan (Tokyo, Japan) and Wako Pure Chemi-
cal Industries Ltd.  All other chemicals were of reagent grade. 
2. Methods 
2.1. Preparation of physical mixtures (PMs) and GMs 
Piroxicam or pranoprofen (0.5 g), a water-soluble polymer (1.5 g), and SDS (0.5 
g) were physically mixed at a weight ratio of 1:3:1 in a glass vial for 5 min by using 
a vortex mixer to obtain PMs.  When HPMC, HM-HPMC, PGA, and HEC were 
used as water-soluble polymers, the PMs were ground by using a vibrational rod mill 
(TI-200; Heiko Seisakusho, Tokyo, Japan) at room temperature for 60 min.  For 
HPC and PVA, the PMs were ground by using a vibrational rod mill (TI-500; Heiko 
Seisakusho) at í180 qC for 60 min. 
2.2. Particle size analysis 
The GM powders were dispersed in distilled water and sonicated for 2 min to 
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form colloidal suspensions.  Particle size was determined by the dynamic light 
scattering method using a Microtrac® ultrafine particle analyzer (Nikkiso, Tokyo, 
Japan; measurement range, 0.003-6 μm). 
2.3. Solubility of the drugs in various PG aqueous solutions 
To determine the solubility of the drugs in various PG aqueous solutions, an 
excess amount of drug was added to each PG aqueous solution and shaken at 32 °C 
in a water bath for 24 h.  The samples were filtered through a 0.45 μm membrane 
filter.  The drug concentration was determined by HPLC. 
2.4. Partition coefficient of the drugs between octanol and PG aqueous solution 
Octanol was presaturated with water, and vice versa.  The appropriate amount of 
drug was added to tubes containing octanol and PG aqueous solution at a ratio of 8:2 
by volume.  The tubes were shaken at 32 °C in a water bath.  After 24 h, the sam-
ples were centrifuged at 3000 rpm for 10 min.  The samples from each phase were 
collected and the drug concentration was quantified by HPLC. 
̆ 59 ̆
2.5. In vitro skin permeation studies 
All animal experiments were approved by the Animal Care and Use Committee 
of the Graduate School of Pharmaceutical Sciences, Chiba University, and SSP Co., 
Ltd. and were carried out in accordance with the guidelines of Principles for the Care 
and Use of Laboratory Animals approved by The Japanese Pharmacological Society.  
The full-thickness dorsal skin of male Hos:HR-1 hairless mice (7-8 weeks old; Japan 
SLC, Inc., Shizuoka, Japan), sacrificed by cervical dislocation, was excised, and 
adherent fat and other visceral debris were removed from the undersurface.  In vitro
permeation studies were carried out with vertical Franz-type diffusion cells at 32 °C.  
The effective area of diffusion was 3.14 cm2, and the receiver cell volume was about 
16.0 mL.  The donor compartment was filled with 0.9 mL of GM suspension 
containing 0.5% w/v piroxicam or 1.0% w/v pranoprofen in a PG aqueous solution.  
The receiver cell was filled with phosphate-buffered saline and 4% w/v albumin 
(modified PBS; pH 7.4) [31] and stirred at 500 rpm with a magnetic stirrer.  Sam-
ples of 0.4 mL were collected at the designated time (2, 4, 6, and 8 h), and the 
amount of permeated piroxicam or pranoprofen was quantified.  The fluid in the 
receiver compartment was replaced with modified PBS at the same volume as each 
withdrawal. 
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2.6. Analytical methods 
2.6.1. Analytical method for piroxicam 
The concentration of piroxicam in the samples was analyzed by HPLC.  The 
HPLC system was constructed with a model L-6000 pump, model L-4000 UV 
detector, and model AS-4000 intelligent autosampler (Hitachi, Ltd., Tokyo, Japan).  
An analytical column, Inertsil ODS-4 (4.6 mm i.d. u 250 mm in diameter, 5 ȝm
particle diameter; GL Sciences, Inc., Tokyo, Japan), and a guard column, L-column 
ODS (4.6 mm i.d. u 10 mm in diameter, 5 ȝm particle diameter; Chemicals Evalua-
tion and Research Institute, Tokyo, Japan), were used with the column heater U-620 
(Sugai Chemie, Inc., Wakayama, Japan) at 40 r 0.5 °C.  The mobile phase consisted 
of acetonitrile and 0.01 M acetic acid/sodium acetate buffer (pH 4.6; 35:65 v/v) was 
used at a flow rate of 1.0 mL/min.  The elution was monitored at an ultraviolet 
wavelength of 365 nm. 
2.6.2. Analytical method for pranoprofen 
The concentration of pranoprofen in the samples was also analyzed by HPLC.  
The HPLC system was the same as mentioned in section 2.6.1.  An analytical 
column, TSK Gel ODS-120T (4.6 mm i.d. u 150 mm in diameter, 5 ȝm particle 
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diameter; Tosoh, Corp., Tokyo, Japan), and a guard column, L-column ODS (4.6 mm 
i.d. u 10 mm in diameter, 5 ȝm particle diameter; Chemicals Evaluation and 
Research Institute), were used with the column heater U-620 (Sugai Chemie, Inc.) at 
40 r 0.5 °C.  The mobile phase consisted of acetonitrile and 0.01 M acetic 
acid/sodium acetate buffer (pH 4.6) (25:75 v/v) was run at a flow rate of 1.0 mL/min.  
The elution was monitored at an ultraviolet wavelength of 275 nm. 
2.7. Data analysis 
The cumulative amount of piroxicam and pranoprofen that permeated into the 
skin was plotted against time.  The skin permeation rate (flux) was calculated from 
the slope of the linear region of the time plot.  Statistical evaluation of data was 
performed by using the F-test followed by Student's t-test (equal variances) or 
Aspin-Welch's t-test (unequal variances). 
2.8. Histological analysis 
For histological observation, back skin was isolated and fixed with 10% 
neutral-buffered formalin for 24 h, dehydrated, and embedded in paraffin.  Then, 
3-μm-thick sections were stained with hematoxylin and eosin according to the 
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standard method.  The sections were observed and photographed with Biozero 
BZ-8100 (Keyence Corporation, Osaka, Japan). 
II. RESULTS AND DISCUSSION
1. Effects of water-soluble polymer and grinding time on mean particle 
size of piroxicam and pranoprofen
To identify additives appropriate for preparing drug nanoparticles having high 
skin permeability, the particle sizes of the GM suspensions were determined using 
ternary components GMs containing drug, water-soluble polymer, and surfactant 
(SDS) [Table I].  The water-soluble polymers used were HEC, HPC, HM-HPMC, 
HPMC, PGA, and PVA.  Among the 6 GM suspensions, it was found that the par-
ticle sizes of the drug were less than 200 nm when HPMC was used as the 
water-soluble polymer. 
The optimal grinding time for nanoparticle formation using HPMC was ex-
amined.  The mean particle sizes of the piroxicam/HPMC/SDS GM were 101, 76, 
71, 68, and 69 nm upon cogrinding for 60, 90, 120, 180, and 240 min, respectively.  
The mean particle size was almost constant with 90 min or more of cogrinding.  
Therefore, the optimal grinding time for piroxicam was fixed as 90 min.  The mean 
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particle sizes of the pranoprofen/HPMC/SDS GM were 165, 146, 146, 301, and 253 
nm on cogrinding for 60, 90, 120, 180, and 240 min, respectively.  The mean 
particle size was the smallest with 90 and 120 min of cogrinding.  Therefore, the 
optimal grinding time for pranoprofen was fixed as 90 min. 
̆ 64 ̆
Table I - Mean particle size of piroxicam and 
pranoprofen prepared by ternary components 
grinding.
Mean particle 
size (nm) 
piroxicam/HEC/SDS a 779 r 98 
piroxicam/HPC/SDS b 699 r 49 
piroxicam/HM-HPMC/SDS a 481 r 57 
piroxicam/HPMC/SDS a 103 r 4 
piroxicam/PGA/SDS a 258 r 28 
piroxicam/PVA/SDS b 848 r 50 
pranoprofen/HEC/SDS a 1197 r 682 
pranoprofen/HPC/SDS b 663 r 176 
pranoprofen/HM-HPMC/SDS a 666 r 43 
pranoprofen/HPMC/SDS a 175 r 6 
pranoprofen/PGA/SDS a 284 r 19 
pranoprofen/PVA/SDS b 862 r 132 
a
  Samples were prepared by grinding of PM at 
room temperature for 60 min. 
b
  Samples were prepared by grinding of PM at 
í180 qC for 60 min. 
Each value represents the mean r S.D. (n = 3).
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2. Stability of nanoparticles in PG aqueous solution
For the skin permeation studies, physical stability of the particle size in PG 
aqueous solution of different PG concentrations was investigated [Figure 1].  The 
mean particle size of the piroxicam/HPMC/SDS GM [Figure 1(a)] and pranopro-
fen/HPMC/SDS GM [Figure 1(b)] in PG aqueous solution of different PG concentra-
tions remained constant for up to 8 h.  These results were consistent with the results 
reported by Wanawongthai et al. [32], where the probucol/PVP/SDS ternary system 
was used.  They suggested that PVP-surfactant complexes formed in the aqueous 
solution entirely covered the surface of probucol nanoparticles thus, preventing the 
rapid agglomeration of particles.  In the case of piroxicam/HPMC/SDS and prano-
profen/HPMC/SDS, it was speculated that HPMC-SDS complexes also formed in the 
aqueous solution entirely covered the surface of drug nanoparticles. 
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Figure 1 - Changes in mean particle size of (a) piroxicam/HPMC/SDS and (b) 
pranoprofen/HPMC/SDS ternary GMs in PG aqueous solution at 32 °C. 
Weight ratio of drug/HPMC/SDS was 1/3/1. 
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3. Comparison of PMs and GMs for skin permeation 
The skin permeation of piroxicam was investigated using ternary PM and GM.  
As shown in Figure 2(a)-(d), the GMs showed significantly higher cumulative 
amount of piroxicam compared to the PMs in all cases.  It was assumed that the 
nanoparticle formation of piroxicam contributed to the enhanced skin permeation.  
Similarly, the cumulative amount of pranoprofen that permeated from the GMs was 
significantly higher than that from the PMs for all PG concentrations [Figure 3].
Many reports have been published regarding the effects of particle size on skin 
permeation.  Vogt et al. [28] reported on the skin permeation of fluorescent material 
containing particles of different sizes (40, 750, and 1500 nm).  They found that 
nanoparticles permeated via hair follicles, and that only nanoparticles of 40 nm in 
size were delivered to the epidermal layer.  Further, Alvarez-Román et al. [27] eva-
luated drug permeation into porcine skin by using non-biodegradable polystyrene 
nanoparticles 20 nm and 200 nm in size containing fluorescent materials.  When 
nanoparticle formulations (20 nm) were applied, fluorescence was detected on the 
skin surface and in the hair follicles after only 0.5 h.  As hair follicles appendages 
occupy only ~ 0.1% of the total skin surface, their net contribution to the total skin 
transport is often considered to be negligible.  They reported that the enhanced deli-
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very into the skin of lipophilic compounds from nanoparticle formulations was not 
attributable to the penetration of the polymer carriers.  Rather, the improved effi-
ciency might be related to efficient liberation of the lipophilic permeants into the 
stratum corneum.  Moribe et al. [30] investigated the permeation of piroxicam from 
nanoparticles prepared by cogrinding with PVP K12 and SDS by using hairless 
mouse skin.  They reported that the skin permeation increased as the particle size of 
piroxicam decreased, and that the particle size should be smaller than 50 nm to en-
hance permeation.  The aforementioned findings suggest that the increased solubil-
ity of piroxicam and pranoprofen due to nanoparticle formation may contribute to the 
enhanced skin permeation of these drugs from nanoparticles. 
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Figure 2 - Amount of piroxicam permeated from piroxicam/HPMC/SDS PMs 
and GMs in (a) distilled water, (b) 10% PG aqueous solution, (c) 30% PG 
aqueous solution, and (d) 50% PG aqueous solution at 32 °C. Weight ratio of 
piroxicam/HPMC/SDS was 1/3/1. Each point represents the mean ± S.D. (n = 
4). **: p < 0.01. 
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Figure 3 - Amount of pranoprofen permeated from pranoprofen/HPMC/SDS 
PMs and GMs in (a) distilled water, (b) 10% PG aqueous solution, (c) 30% PG 
aqueous solution, and (d) 50% PG aqueous solution at 32 °C. Weight ratio of 
pranoprofen/HPMC/SDS was 1/3/1. Each point represents the mean ± S.D. (n 
= 3 ~ 4). *: p < 0.05, **: p < 0.01. 
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4. Effects of grinding composition on skin permeation 
The effects of grinding compositions on the skin permeation of piroxicam was 
investigated using the piroxicam/HPMC binary GM (weight ratio, 1:3) and the pirox-
icam/HPMC/SDS ternary GM (weight ratio, 1:3:1) [Figure 4(a)].  Powder X-ray 
diffraction measurements demonstrated that piroxicam existed in a crystalline state in 
the piroxicam/HPMC GM and piroxicam/HPMC/SDS GM.  The cumulative 
amount of piroxicam permeated from the piroxicam/HPMC/SDS GM in distilled wa-
ter was significantly higher than that from the piroxicam/HPMC GM, although no 
significant difference in particle size was observed between the GMs.  Therefore, it 
is presumed that the third composition (SDS) played an important role for enhanced 
skin permeation.  Moribe et al. [30] investigated the piroxicam skin permeation us-
ing a piroxicam/PVP K12/SDS ternary GM (weight ratio of 1:3:1), and a pirox-
icam/PVP K12 binary GM (weight ratio, 1:3) using hairless mouse skin, where 
piroxicam was in the crystalline state in ternary GM and in the amorphous state in 
binary GM.  They found that the ternary GM provided a significantly higher 
cumulative amount of piroxicam than the binary GM.  They concluded that the 
enhanced skin permeation of piroxicam was attributable mainly to the nanoparticle 
formation (mean particle size, 23 nm), but not to the dispersion state of the drug 
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molecules.
When the skin permeation from the piroxicam/SDS GM (weight ratio of 1:1) was 
compared with that from the piroxicam/HPMC/SDS GM, the cumulative amount of 
piroxicam permeated was found to be significantly higher for the binary GM than for 
the ternary GM [Figure 4(b)].  The enhanced skin permeation, however, may be 
attributable to skin damage caused by SDS.  The microscopical observation was 
performed for hairless mouse skin after 8 h of treatment using hematoxylin and eosin 
staining.  In the case of the skin to which the piroxicam/SDS GM was applied, the 
stratum corneum substantially disappeared, the epidermis peeled off, and dermal 
cells underwent necrosis, as shown in Figure 5(b).  These results were very similar 
to the findings reported by Griffiths et al. [33] about skin irritation by SDS.  No 
skin damage, however, was observed in the skin to which the piroxicam/HPMC/SDS 
GM was applied [Figure 5(a)]; the histological section was comparable to that of the 
untreated skin shown in Figure 5(c).  It was known that SDS formed a complex 
with PVP during ternary cogrinding [32]; this complex formation influenced the sur-
face activity of SDS in water.  Nilsson reported that SDS interacted with HPMC 
depending on its concentration [34].  The system HPMC/SDS/water has been 
investigated over an extended composition interval and concentration range.  They 
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found that the maximum capacity of adsorption averaged over the entire polymer 
chain is found to be in the order of 1 adsorbed SDS per polymer monomer unit.  
The adsorbed amount of SDS per HPMC glucose unit is ca 0.2 in this study.  There-
fore, complex formation between HPMC and SDS may result in the reduction of skin 
damage caused by SDS. 
Figure 4(c) shows the effects of grinding composition on the skin permeation of 
pranoprofen using pranoprofen/HPMC binary GM (weight ratio, 1:3) and pranopro-
fen/HPMC/SDS ternary GM (weight ratio, 1:3:1).  The particle size of the 
pranoprofen/HPMC GM suspension was 1.09 μm, which was about 7.5-fold larger 
than that in the pranoprofen/HPMC/SDS GM.  In the pranoprofen/HPMC binary 
GM, pranoprofen existed in an amorphous state, while in the pranopro-
fen/HPMC/SDS GM, pranoprofen was in a partially crystalline state.  The 
pranoprofen/HPMC/SDS ternary GM provided a higher cumulative permeation 
amount of pranoprofen than the pranoprofen/HPMC binary GM.  The enhanced 
skin permeation of pranoprofen may be attributable to nanoparticle formation, but 
not to its dispersion state.  From the results on piroxicam [Figures 4(b) and 5], it 
was suggested that the pranoprofen/SDS binary GM results in skin damage caused 
by SDS.  The aforementioned results suggest that the ternary grinding of a drug, 
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HPMC, and SDS was indispensable and essential for nanoparticle formation and for 
enhancement of the skin permeation of piroxicam and pranoprofen. 
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Figure 4 - Effect of grinding composition on amount of piroxicam and 
pranoprofen permeated from binary (open circle) and ternary (closed circle) 
GMs dispersed in distilled water at 32 °C: (a) piroxicam/HPMC and pirox-
icam/HPMC/SDS, (b) piroxicam/SDS and piroxicam/HPMC/SDS, and (c) 
pranoprofen/HPMC and pranoprofen/HPMC/SDS. Weight ratio of drug/HPMC 
and drug/SDS was 1/3 and 1/1, respectively. Each point represents the mean 
± S.D. (n = 3 ~ 4). *: p < 0.05, **: p < 0.01. 
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Figure 5 - Histological sections of hairless mouse skin stained with hematox-
ylin and eosin at 8 h after application of (a) piroxicam/HPMC/SDS, (b) pirox-
icam/SDS GMs in distilled water, and (c) Untreated skin. Weight ratio of 
piroxicam/SDS was 1/1. The stratum corneum appears at the top with a red 
stain. Viable epidermis is immediately below with characteristic blue staining 
of epidermal cell nuclei. The pink-stained dermis is below the epidermis. Stra-
tum corneum: SC, Viable epidermis: VE, Dermis: D 
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5. Effects of PG concentration on skin permeation 
Figure 2(a)-(d) shows the results of in vitro skin permeation of piroxicam.  It 
was found that the cumulative amounts of permeated piroxicam from ternary GMs 
suspension were independent of the PG concentration.  On the other hand, the 
cumulative amount of permeated pranoprofen from ternary GMs increased as the 
PG concentration increased [Figure 3].
Fluxes were calculated using the data of the cumulative amounts of permeated 
piroxicam and pranoprofen [Figure 6].  As shown in Figure 6(a), the flux of pirox-
icam from the piroxicam/HPMC/SDS GM through hairless mouse skin was signifi-
cantly higher than that from the piroxicam/HPMC GM or piroxicam/HPMC/SDS PM.  
The fluxes of piroxicam from the piroxicam/HPMC/SDS GMs in PG aqueous solu-
tion of different concentrations were almost comparable, demonstrating that they 
were independent of the PG concentrations.  As shown in Figure 6(b), the flux of 
pranoprofen from the pranoprofen/HPMC/SDS GM through hairless mouse skin was 
significantly higher than that from the pranoprofen/HPMC GM or pranopro-
fen/HPMC/SDS PM.  Unlike the fluxes of piroxicam, the fluxes of pranoprofen 
from the pranoprofen/HPMC/SDS GMs increased depending on the PG concentra-
tion in the suspension.  Moribe et al. have reported about the skin permeation of 
piroxicam by using PVP ternary GM [30].  There was no significant difference in 
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the fluxes between HPMC ternary GM and PVP ternary GM: 0.96 ȝg/cm2/h for a 
piroxicam/HPMC/SDS GM suspension with a particle size of 76 nm and 1.07 
ȝg/cm2/h for a piroxicam/PVP K12/SDS GM suspension with a particle size of 23 
nm.  The cumulative amount after 8 h permeation slightly increased depending on 
the particle size: 6.25 r 0.53 ȝg/cm2 for the piroxicam/HPMC/SDS GM and 8.31 r
1.56 ȝg/cm2 for the piroxicam/PVP K12/SDS GM.  This comparison demonstrated 
that both HPMC and PVP had similar ability for nanoparticle formation and permea-
tion enhancement. 
Several reports have been published on the effects of PG on skin permeation.  
Irwin et al. [35] reported the effects of PG on rat skin permeation of ibuprofen.  The 
maximum ibuprofen permeability was observed at a PG concentration of 20%, show-
ing strong dependency of permeability on the partition coefficient of ibuprofen be-
tween octanol and the aqueous phase.  Pellett et al. [36] investigated the effect of 
solubility on in vitro permeation of piroxicam through silicone membranes and hu-
man skin.  The solubility difference for piroxicam obtained from various PG 
aqueous solutions was highly correlated with the flux of piroxicam through a silicone 
membrane: the flux increased as the solubility increased.  Ross and Shah [37] ex-
amined the relationship between human skin permeation of a lipophilic drug and the 
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skin-vehicle partition coefficient.  The water solubility of N,N-diethyl-m-toluamide 
(DEET) increased and the octanol-water partition coefficient linearly decreased as 
the concentrations of PG increased.  The flux of DEET through human skin de-
creased as the PG concentration increased.  They concluded that decreased partition 
coefficients affected the reduced skin permeation of DEET.  From the references, 
the fact that the cumulative amount of pranoprofen depended on the PG concentra-
tion and that of piroxicam was independent of the PG concentration could be as-
cribed to the different solubility and partition coefficients of piroxicam and pranopro-
fen in PG aqueous solution. 
The solubilities of piroxicam and pranoprofen in PG aqueous solution of different 
concentrations and the partition coefficient (K) in an octanol-PG aqueous solution 
were determined [Figure 7].  The solubility of piroxicam in distilled water was 0.02 
r 0.01 mg/mL, and that in a 50% PG aqueous solution was 0.24 r 0.00 mg/mL at 
32 °C, demonstrating a 12-fold increase for a 50% PG aqueous solution.  The 
solubility of pranoprofen in distilled water was 0.06 r 0.01 mg/mL and that in a 50% 
PG aqueous solution was 1.14 r 0.02 mg/mL, demonstrating a 19-fold increase for a 
50% PG aqueous solution.  Pranoprofen showed a marked solubility increase com-
pared to piroxicam by increase in PG concentration.  Further, the partition coeffi-
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cients (Log K) of piroxicam were 0.51 r 0.03 for octanol-distilled water and í0.23 r
0.02 for an octanol-50% PG aqueous solution, and those of pranoprofen were 0.52 r
0.04 for distilled water and í0.02 r 0.02 for a 50% PG aqueous solution.  The 
octanol-water partition coefficients were comparable between piroxicam and 
pranoprofen in low PG concentration solution, while at high PG concentrations, the 
partition coefficient of piroxicam was smaller than that of pranoprofen. 
Pellett et al. [38] described that the partition coefficient (K) of piroxicam between 
the silicone membrane and PG aqueous solution decreased as the PG concentration 
increased.  They also reported that the products of solubility and K of piroxicam 
were almost constant in the range of 0-50% PG aqueous solution.  Regarding the 
relationship between flux, concentration, and partition coefficients, the following 
equation is reported [39]: 
 J = DKC/h Eq. 1
where J is the flux of the drug through the skin, D is the diffusion coefficient, K is 
the partition coefficient, C is the drug concentration in a vehicle solution, and h is the 
membrane thickness.  In an ideal system, as h and D are assumed to be constant, 
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flux is proportional to the product of K and C.  The products of partition coefficient 
and solubility of piroxicam in PG aqueous solution were estimated to be 0.06, 0.11, 
0.12, and 0.14 for distilled water, 10%, 30%, and 50% PG, respectively.  The fluxes 
showed similar value even when the PG concentration varied from 0% to 50%.  On 
the other hand, the products of partition coefficient and solubility of pranoprofen 
were 0.20, 0.12, 0.48, and 1.08 for distilled water and 10%, 30% and 50% PG solu-
tions.  It is possible that the solubility of pranoprofen in PG aqueous solution altered 
to a great extent compared to piroxicam.  It was concluded that the flux of 
pranoprofen in PG aqueous solution increased according to the PG concentration.  
When the piroxicam GM or PM was suspended in a PG aqueous solution, the pirox-
icam seemed to be in supersaturated condition for the GM and in a saturated condi-
tion for the PM.  As the partition constant is a characteristic value of the drug, the 
partition coefficient is assumed to be constant for GM and PM.  Therefore, Equa-
tion 1 leads to: 
 JGM/JPM = CGM/CPM Eq. 2
where JGM and JPM are the fluxes of GM and PM, respectively, and CGM and CPM are 
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the concentrations of GM and PM in a donor solution, respectively, considering that 
CPM represents the saturated concentration and JGM/JPM represents the degree of 
supersaturation.  Upon substituting the fluxes of the GM and PM of piroxicam in 
Equation 2, the degrees of saturation of piroxicam in distilled water and 10%, 30%, 
and 50% PG aqueous solution were 2.59, 3.12, 3.56, and 2.66, respectively, suggest-
ing constant supersaturated conditions of piroxicam.  Substitution of the fluxes of 
the GM and PM of pranoprofen in Equation 2 yielded the values 1.88, 2.30, 2.79, 
and 3.48 in distilled water and 10%, 30%, and 50% PG aqueous solution, respec-
tively, also suggesting supersaturated conditions in the case of pranoprofen.  The 
markedly enhanced skin permeation of the piroxicam and pranoprofen GMs was 
attributable to the supersaturated state of the drugs in suspension.  The medicinal 
molecules that penetrated the skin should be replaced from the nanocrystal surfaced, 
in order to maintain a constant supersaturation level. 
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Figure 6 - Skin permeation parameters of (a) piroxicam and (b) pranoprofen 
from drug/HPMC/SDS GM, drug/HPMC GM, and drug/HPMC/SDS PM in PG 
aqueous solution at 32 °C. Each point represents the mean ± S.D. (n = 3 ~ 4). 
*: p < 0.05, **: p < 0.01. 
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Figure 7 - Solubility (C: closed symbol) and partition coefficient (Log K: open 
symbol) of piroxicam (circle) and pranoprofen (square) in PG aqueous 
solution at 32 °C. Each point represents the mean ± S.D. (n = 3). 
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Piroxicam and pranoprofen nanoparticles could be formed by ternary cogrinding 
with HPMC as a water-soluble polymer and SDS.  The suspension of ternary GMs 
of piroxicam and/or pranoprofen in PG aqueous solution markedly enhanced the skin 
permeation of the drugs, without skin damage.  The enhanced skin permeation may 
be attributable to their supersaturation due to nanoparticle formation.  It was found 
that piroxicam ternary GM suspension showed high and improved skin permeation 
that did not depend on the PG concentration of the media, while the permeation 
amount of pranoprofen increased with increasing PG concentrations.  This differ-
ence in skin permeation may be attributable to the different solubilities of the drugs 
in PG aqueous solution. 
These results will help reveal the mechanism of skin permeation of drugs from 
nanoparticle suspensions.  The enhanced skin permeation of nanoparticle drugs, ob-
served for both HPMC and PVP, is suggestive of further applications of 
water-soluble polymers in the development of external preparations. 
̆ 86 ̆
ACKNOWLEDGEMENTS 
We thank Ms. K. Kaneko, Mr. Y. Matsunawa, and Ms. Y. Mori for their technical 
assistance. 
̆ 87 ̆
REFERENCES 
1. Merisko-Liversidge E., Liversidge G.G., Cooper E.R. - Nanosizing: a 
formulation approach for poorly-water-soluble compounds. - Eur. J. 
Pharm. Sci., 18, 113-120, 2003. 
2. Zili Z., Sfar S., Fessi H. - Preparation and characterization of 
poly-İ-caprolactone nanoparticles containing griseofulvin. - Int. J. 
Pharm., 294, 261-267, 2005. 
3. Jinno J., Kamada N., Miyake M., Yamada K., Mukai T., Odomi M., 
Toguchi H., Liversidge G.G., Higaki K., Kimura T. - Effect of particle 
size reduction on dissolution and oral absorption of a poorly 
water-soluble drug, cilostazol, in beagle dogs. - J. Control. Release, 
111, 56-64, 2006. 
4. Matteucci M.E., Brettmann B.K., Rogers T.L., Elder E.J., Williams III 
R.O., Johnston K.P. - Design of potent amorphous drug nanoparticles 
for rapid generation of highly supersaturated media. - Mol. Pharm., 4,
782-793, 2007. 
5. Mihranyan A., Strømme M. - Solubility of fractal nanoparticles. - Surf. 
̆ 88 ̆
Sci., 601, 315-319, 2007. 
6. Wu J.Z., Ho P.C. - Evaluation of the in vitro activity and in vivo
bioavailability of realgar nanoparticles prepared by cryo-grinding. - 
Eur. J. Pharm. Sci., 29, 35-44, 2006. 
7. Pongpeerapat A., Wanawongthai C., Tozuka Y., Moribe K., Yamamoto 
K. - Formation mechanism of colloidal nanoparticles obtained from 
probucol/PVP/SDS ternary ground mixture. - Int. J. Pharm., 352,
309-316, 2008. 
8. Shudo J., Pongpeerapat A., Wanawongthai C., Moribe K., Yamamoto 
K. - In vivo assessment of oral administration of probucol nanopar-
ticles in rats. - Biol. Pharm. Bull., 31, 321-325, 2008. 
9. Fukami T., Ishii T., Io T., Suzuki N., Suzuki T., Yamamoto K., Xu J., 
Ramamoorthy A., Tomono K. - Nanoparticle processing in the solid 
state dramatically increases the cell membrane permeation of a 
cholesterol-lowering drug, probucol. - Mol. Pharm., 6, 1029-1035, 
2009.
10. Bisht S., Feldmann G., Koorstra J.M., Mullendore M., Alvarez H., 
Karikari C., Rudek M.A., Lee C.K., Maitra A., Maitra A. - In vivo
̆ 89 ̆
characterization of a polymeric nanoparticle platform with potential 
oral drug delivery capabilities. - Mol. Cancer Ther., 7, 3878-3888, 
2008.
11. Shaikh J., Ankola D.D., Beniwal V., Singh D., Ravi Kumar M.N.V. - 
Nanoparticle encapsulation improves oral bioavailability of curcumin 
by at least 9-fold when compared to curcumin administered with 
piperine as absorption enhancer. - Eur. J. Pharm. Sci., 37, 223-230, 
2009.
12. Grenha A., Remuñán-López C., Carvalho E.L.S., Seijo B. - 
Microspheres containing lipid/chitosan nanoparticles complexes for 
pulmonary delivery of therapeutic proteins. - Eur. J. Pharm. Biopharm., 
69, 83-93, 2008. 
13. Rajapaksa T.E., Stover-Hamer M., Fernandez X., Eckelhoefer H.A., 
Lo D.D. - Claudin 4-targeted protein incorporated into PLGA nanopar-
ticles can mediate M cell targeted delivery. - J. Control. Release, 142,
196-205, 2010. 
14. Merisko-Liversidge E., McGurk S.L., Liversidge G.G. - Insulin 
nanoparticles: a novel formulation approach for poorly water soluble 
̆ 90 ̆
Zn-insulin. - Pharm. Res., 21, 1545-1553, 2004. 
15. Patil Y., Sadhukha T., Ma L., Panyam J. - Nanoparticle-mediated 
simultaneous and targeted delivery of paclitaxel and tariquidar 
overcomes tumor drug resistance. - J. Control. Release, 136, 21-29, 
2009.
16. Singka G.S.L., Samah N.A., Zulfakar M.H., Yurdasiper A., Heard C.M. 
- Enhanced topical delivery and anti-inflammatory activity of 
methotrexate from an activated nanogel. - Eur. J. Pharm. Biopharm., 
76, 275-281, 2010. 
17. Zhao Y., Brown M.B., Jones S.A. - The effects of particle properties on 
nanoparticle drug retention and release in dynamic minoxidil foams. - 
Int. J. Pharm., 383, 277-284, 2010. 
18. Cheong H., Choi H. - Enhanced percutaneous absorption of pirox-
icam via salt formation with ethanolamines. - Pharm. Res., 19,
1375-1380, 2002. 
19. Zhao L., Li Y., Fang L., Ren C., Xu Y., He Z. - Effect of O-acylmenthol
and salt formation on the skin permeation of diclofenac acid. - Drug 
Dev. Ind. Pharm., 35, 814-826, 2009. 
̆ 91 ̆
20. Cilurzo F., Minghetti P., Alberti E., Gennari C.G.M., Pallavicini M., 
Valoti E., Montanari L. - An investigation into the influence of counte-
rion on the RS-propranolol and S-propranolol skin permeability. - J. 
Pharm. Sci., 99, 1217-1224, 2010. 
21. Murthy S.N., Zhao Y., Sen A., Hui S.W. - Cyclodextrin enhanced 
transdermal delivery of piroxicam and carboxyfluorescein by 
electroporation. - J. Control. Release, 99, 393-402, 2004. 
22. Ventura C.A., Tommasini S., Falcone A., Giannone I., Paolino D., 
Sdrafkakis V., Mondello M.R., Puglisi G. - Influence of modified 
cyclodextrins on solubility and percutaneous absorption of celecoxib 
through human skin. - Int. J. Pharm., 314, 37-45, 2006. 
23. Mora M.J., Longhi M.R., Granero G.E. - Synthesis and characteriza-
tion of binary and ternary complexes of diclofenac with a methyl-E-CD 
and monoethanolamine and in vitro transdermal evaluation. - Eur. J. 
Med. Chem., 45, 4079-4088, 2010. 
24. Williams A.C., Barry B.W. - Penetration enhancers. - Adv. Drug Deliv. 
Rev., 56, 603-618, 2004. 
25. Kimura C., Nakanishi T., Tojo K. - Skin permeation of ketotifen applied 
̆ 92 ̆
from stick-type formulation. - Eur. J. Pharm. Biopharm., 67, 420-424, 
2007.
26. Cho C., Choi J., Yang K., Shin S. - Enhanced transdermal absorption 
and pharmacokinetic evaluation of pranoprofen ethylene vinyl acetate 
matrix containing penetration enhancer in rats. - Arch. Pharm. Res., 
32, 747-753, 2009. 
27. Alvarez-Román R., Naik A., Kalia Y.N., Guy R.H., Fessi H. - Skin 
penetration and distribution of polymeric nanoparticles. - J. Control. 
Release, 99, 53-62, 2004. 
28. Vogt A., Combadiere B., Hadam S., Stieler K.M., Lademann J., 
Schaefer H., Autran B., Sterry W., Blume-Peytavi U. - 40 nm, but not 
750 or 1,500 nm, nanoparticles enter epidermal CD1a cells after 
transcutaneous application on human skin. - J. Invest. Dermatol., 126,
1316-1322, 2006. 
29. Tsujimoto H., Hara K., Tsukada Y., Huang C.C., Kawashima Y., 
Arakaki M., Okayasu H., Mimura H., Miwa N. - Evaluation of the 
permeability of hair growing ingredient encapsulated PLGA nanos-
pheres to hair follicles and their hair growing effects. - Bioorg. Med. 
̆ 93 ̆
Chem. Lett., 17, 4771-4777, 2007. 
30. Moribe K., Shibata M., Furuishi T., Higashi K., Tomono K., Yamamoto 
K. - Effect of particle size on skin permeation and retention of pirox-
icam in aqueous suspension. - Chem. Pharm. Bull., 58, 1096-1099, 
2010.
31. Moser K., Kriwet K., Froehlich C., Kalia N.Y., Guy R.H. - 
Supersaturation: enhancement of skin penetration and permeation of 
a lipophilic drug. - Pharm. Res., 18, 1006-1011, 2001. 
32. Wanawongthai C., Pongpeerapat A., Higashi K., Tozuka Y., Moribe K., 
Yamamoto K. - Nanoparticle formation from probucol/PVP/sodium 
alkyl sulfate co-ground mixture. - Int. J. Pharm., 376, 169-175, 2009. 
33. Griffiths H.A., Wilhelm K.P., Robinson M.K., Wang X.M., Mcfadden J., 
York M., Basketter D.A. - Interlaboratory evaluation of a human patch 
test for the identification of skin irritation potential/hazard. - Food 
Chem. Toxicol., 35, 255-260, 1997. 
34. Nilsson S. - Interactions between water-soluble cellulose derivatives 
and surfactants. 1. The HPMC/SDS/water system. – Macromolecules, 
28, 7837-7844, 1995. 
̆ 94 ̆
35. Irwin W.J., Sanderson F.D., Li Wan Po A. - Percutaneous absorption 
of ibuprofen: vehicle effects on transport through rat skin. - Int. J. 
Pharm., 66, 193-200, 1990. 
36. Pellett M.A., Castellano S., Hadgraft J., Davis A.F. - The penetration 
of supersaturated solutions of piroxicam across silicone membranes 
and human skin in vitro. - J. Control. Release, 46, 205-214, 1997. 
37. Ross J.S., Shah J.C. - Reduction in skin permeation of 
N,N-diethyl-m-toluamide (DEET) by altering the skin/vehicle partition 
coefficient. - J. Control. Release, 67, 211-221, 2000. 
38. Pellett M.A., Davis A.F., Hadgraft J. - Effect of supersaturation on 
membrane transport: 2. Piroxicam. - Int. J. Pharm., 111, 1-6, 1994. 
39. Walters K.A. - Dermatological and transdermal formulations. - In: 
Watkinson A.C., Brain K.R. (Eds.), Basic Mathematical Principles in 
Skin Permeation, Marcel Dekker Inc., New York, 2002, pp. 65-73. 
